Dr. Timothy N. Liesching, MD

Dr. Liesching practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Liesching's NPI, 1730136433, was assigned on May 28, 2006. Dr. Liesching graduated from State University of New York at Buffalo School of Medicine in 1997. Dr. Liesching holds Massachusetts license 159623.

Dr. Liesching's primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Liesching's primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Liesching to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Liesching practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Liesching's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Liesching is licensed in Massachusetts.

CMS data shows 93 Medicare services from Dr. Liesching across 3 procedure codes in 2024, for 72 Medicare patients. Medicare paid $6,616 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 72 Medicare patients who saw Dr. Liesching in 2024. The largest group is 75 to 84, with 30 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Liesching's median patient age at 68, with 47% women.

In 2024, Dr. Liesching wrote 243 Medicare Part D claims for 54 patients. 40% of them were for generic drugs. CMS names the drug for 134 of them, across 8 drugs with 11 or more claims each, at $40,041 in total drug cost. In 2023, CMS named 196 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Liesching for performance year 2024, reported through an alternative payment model (APM).

Dmand AI links 18 papers to Dr. Liesching, published from 2011 to 2023. 2021 was the busiest year, with 3. The most frequent topics are Early Detection of Cancer, Lung Neoplasms and Length of Stay. Dr. Liesching has published most often in Int J Crit Illn Inj Sci. Dr. Liesching's most frequent co-authors are Lee Gazourian, MD, Carla R. Lamb, MD and Avignat S. Patel, MD.

Dmand AI links Dr. Liesching to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Idiopathic Pulmonary Fibrosis, Severe Acute Respiratory Syndrome and COVID-19.

CMS Open Payments shows 25 general payments to Dr. Liesching from 5 drug and device companies from 2017 to 2023. Speaker and faculty fees make up the largest share, 82% of the total. AstraZeneca Pharmaceuticals LP paid the most, $7,548.

Dr. Liesching graduated from State University of New York at Buffalo School of Medicine in 1997.